Cidara Therapeutics

197 articles about Cidara Therapeutics

• Cidara Therapeutics Announces Closing of Rights Offering

  2/12/2020

  SAN DIEGO, Feb. 12, 2020 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX) (“Cidara”) today announced the closing of its previously announced rights offering (the “Rights Offering”). At the closing, Cidara sold and issued an aggregate of 6,639,307 shares of its common stock (the “Common Stock”) and an aggregate of 531,288 shares of its Series X convertible preferred stock (“Series X Preferred Stock”), pursuant to the exercise of subscription rights in the Rights Offering from its ex

• Cidara Therapeutics Announces Commencement of Rights Offering

  1/22/2020

  Cidara Therapeutics, Inc. (Nasdaq: CDTX) (“Cidara”) today commenced the previously announced rights offering to raise gross proceeds of approximately $30.0 million (the “Rights Offering”)

• Cidara Therapeutics Announces Proposed Rights Offering

  1/10/2020

  Rights Offering will be available to all stockholders and 2018 warrant holders of record on January 21, 2020

• Cidara Therapeutics to Present at Two Upcoming Medical Conferences ASH presentation will include new preclinical data on rezafungin for prevention of Pneumocystis

  12/3/2019

  Cidara Therapeutics, Inc. announced that it will present a poster at the 61st American Society of Hematology Annual Meeting & Exposition, which takes place Dec 7-10, 2019, in Orlando, Fl, and will deliver an oral presentation at the 39th Interdisciplinary Meeting on Anti-Infective Chemotherapy, which takes place Dec 16-17, 2019 in Paris.

• Cidara Therapeutics Named a San Diego Metro Area Top Workplace for the Third Consecutive YearEmployee feedback places Cidara among top small companies in the area

  11/18/2019

  Cidara Therapeutics, Inc., a biotechnology company developing novel anti-infectives including immunotherapies, announced that it has been named a Top Workplace by The San Diego Union-Tribune for the third consecutive year.

• Cidara Provides Corporate Update and Reports Third Quarter 2019 Financial Results

  11/8/2019

  Cidara Therapeutics, Inc. reported financial results for the three months ended September 30, 2019 and provided an update on its corporate activities and product pipeline.

• Cidara Therapeutics Hosting Key Opinion Leader Meeting on Rezafungin and Cloudbreak Programs

  11/5/2019

  Cidara Therapeutics, Inc. announced that it will host a Key Opinion Leader meeting on its rezafungin and Cloudbreak programs on November 14 in New York City for institutional investors, sell-side analysts, and business development professionals.

• Cidara Therapeutics and Mundipharma Form Strategic Partnership to Develop and Commercialize Rezafungin

  9/3/2019

  Cidara Therapeutics, Inc. and Mundipharma announced that they have entered into a strategic partnership to develop and commercialize rezafungin for the treatment and prevention of invasive fungal infections.

• Cidara Therapeutics to Present Data from its Cloudbreak Antiviral Program at the Options X for the Control of Influenza Conference

  8/21/2019

  Five abstracts, including one late-breaker, highlighting data from its Cloudbreak® antiviral program have been accepted for presentation at the Options X for the Control of Influenza conference taking place August 28-September 1 in Singapore.

• 

  Clinical Catch-up for July 29 – August 2

  8/5/2019

  Every week brings news of clinical trials, ranging from launches, first-patient dosing, full enrollment, interim data or final data. Here’s a look at some of the clinical trial news from last week.

• Cidara Therapeutics Reports Positive Topline Results in Phase 2 STRIVE B Trial of Antifungal Rezafungin.

  7/29/2019

  Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives, including immunotherapies, today reported positive topline results from Part B of the global Phase 2 STRIVE trial evaluating the company’s lead antifungal candidate rezafungin.

• Cidara Therapeutics to Present New Data on Rezafungin and its Cloudbreak Antiviral Candidate for Influenza at ASM Microbe 2019

  6/5/2019

  Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that new data from studies of rezafungin, the company’s Phase 3 antifungal, and CB-012, its Cloudbreak® antiviral Fc-conjugate (AVC) candidate for influenza, will be presented at the American Society for Microbiology (ASM) Microbe 2019 annual meeting taking place June 20-24 in San Francisco.

• 

  Cidara Tackles Anti-Fungal Therapies, Takes Aim at Universal Flu Treatment

  5/1/2019

  While few drug developers are focused on multi-drug resistant invasive fungal infections, San Diego-based Cidara Therapeutics is in the thick of the fight with its Phase III lead antifungal rezafungin.

• Cidara Therapeutics Highlights New Data from Multiple Rezafungin Studies Presented at ECCMID 2019

  4/16/2019

  Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, highlighted new data from multiple studies of rezafungin, the company’s lead investigational compound, this week during the 29th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) in Amsterdam, Netherlands.

• Cidara Therapeutics Selects First Clinical Development Candidate from its Cloudbreak Influenza (Antiviral) Program

  4/15/2019

  CB-012 demonstrates potent antiviral activity against influenza A and B viruses

• Cidara Therapeutics Announces Multiple Presentations at the 29th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)

  3/26/2019

  Four oral presentations include first scientific presentation of new data highlighting the potential of its Cloudbreak antiviral conjugates (AVCs) for influenza

• Cidara Therapeutics Announces Rezafungin Presentations at the 2019 Transplantation and Cellular Therapy (TCT) Meeting

  2/5/2019

  Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that data from studies of its lead antifungal rezafungin will be presented at the 2019 Transplantation and Cellular Therapy (TCT) Meeting of ASBMT and CIBMTR (formerly the BMT Tandem Meetings) to be held in Houston, Texas from February 20-24, 2019.

• Cidara Therapeutics Appoints James Levine as CFO and Jessica Oien as General Counsel and Secretary

  12/3/2018

  Cidara Therapeutics today announced the appointments of James Levine as chief financial officer and Jessica Oien, J.D., as general counsel and secretary.

• Cidara Therapeutics to Present New Data at ASH 2018 Highlighting Potential of Rezafungin to Prevent Invasive Fungal Infections in Bone Marrow Transplant Patients

  11/27/2018

  Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that the company will present new data highlighting the potential of rezafungin to prevent invasive fungal infections in bone marrow transplantation (BMT) patients at the 60th American Society of Hematology (ASH) Annual Meeting.

• Cidara Therapeutics Named a San Diego Metro Area Top Workplace for Second Consecutive Year

  11/12/2018

  Employee feedback places Cidara among top 15 small companies in the area